%0 Journal Article
%T New insights into the role and mechanism of macrophage migration inhibitory factor in steroid-resistant patients with systemic lupus erythematosus
%A Fang-Fang Wang
%A Li-An Zhu
%A Yu-Qiong Zou
%A Hui Zheng
%A Alisa Wilson
%A Cheng-De Yang
%A Nan Shen
%A Daniel J Wallace
%A Michael H Weisman
%A Shun-Le Chen
%A Liang-Jing Lu
%J Arthritis Research & Therapy
%D 2012
%I BioMed Central
%R 10.1186/ar3828
%X Sixty-two patients with SLE (40 steroid sensitive and 22 steroid resistant) and 21 normal controls were recruited. Serum levels of MIF were measured by ELISA. Cytosolic MIF and I百B expression in peripheral blood mononuclear cells (PBMCs) were determined by western blotting. The electrophoretic mobility shift assay was assessed by NF-百B in nuclear aliquots. Gene silencing was applied to reduce expression of MIF in PBMCs in steroid-resistant patients. PBMCs obtained from steroid-sensitive patients were treated with recombinant human MIF of different concentrations.MIF levels in serum and PBMCs were higher in steroid-resistant patients compared with steroid-sensitive patients and controls. In contrast to the steroid-sensitive group, NF-百B levels were significantly higher and I百B levels lower in steroid-resistant patients. After MIF gene silencing, I百B levels in cells from steroid-resistant patients were increased. In steroid-sensitive patients, a decrease in I百B levels and an increase in NF-百B expression from baseline were detected in PBMCs treated with a higher concentration of recombinant human MIF. Treatment with recombinant human MIF did not regulate expression of I百B and NF-百B in PBMCs from patients treated with an anti-MIF monoclonal antibody.Our results indicated that MIF may play a role in the formation of steroid resistance in SLE by affecting the NF-百B/I百B signaling cascade. As a regulator of glucocorticoid sensitivity, MIF may be a potential target for steroid sparing.Systemic lupus erythematosus (SLE) is a prototype systemic autoimmune disease characterized by autoantibody production. Although the outcome for SLE patients has improved in recent years, SLE continues to profoundly affect health status and the likelihood of disability and premature death. How to ameliorate the reduced quality of life and increase the survival rate in these patients remains a major challenge for rheumatologists. Glucocorticoid (GC) therapy plays an important role in the treatme
%U http://arthritis-research.com/content/14/3/R103